Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Scottsbluff, NE
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Scottsbluff, NE
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Las Vegas, NV
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Reno, NV
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lebanon, NH
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Bayonne, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Bayonne, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Denville, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Denville, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Edison, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Edison, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Flemington, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Flemington, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Freehold, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
LawrenceVille, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
LawrenceVille, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Livingston, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Livingston, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Newark, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Paterson, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Paterson, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Stratford, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Stratford, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Teaneck, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
West Long Branch, NJ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
West Long Branch, NJ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Alburquerque, NM
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Alburquerque, NM
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Albany, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Amherst, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Amherst, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Bay Shore, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Bay Shore, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Brooklyn, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Buffalo, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Camillus, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Camillus, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Cedarhurst, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Corning, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Corning, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
East Meadow, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
East Meadow, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
East Syracuse, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
East Syracuse, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Flushing, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Flushing, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fresh Meadows, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fresh Meadows, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Great Neck, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Kingston, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Kingston, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lake Success, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Latham, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Latham, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Mineola, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Mineola, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Mount Kisco, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
New Hyde Park, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
New York, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Newark, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Newark, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Patchogue, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Patchogue, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Plainview, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Plainview, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Poughkeepsie, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Rochester, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Rye Brook, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Rye Brook, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Schenectady, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Schenectady, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Staten Island, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Stony Brook, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Syracuse, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
West Seneca, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
West Seneca, NY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
White Plains, NY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
White Plains, NY
Click here to add this to my saved trials